BMR.H Bradmer Pharmaceuticals

Bradmer Pharmaceuticals Inc. (TSX VENTURE: BMR.H) announced today that it has granted, subject to regulatory approval, options to directors and officers of the company exercisable to acquire an aggregate of 1,500,000 common shares, at a price of $0.10 per share, expiring July 21, 2021.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contacts: Bradmer Pharmaceuticals Inc. Paul Van Damme 416.987.6113 pvandamme@bradmerpharma.com